Cardiovascular Physiology
Cardiovascular diseases are the leading cause of death and represent the heaviest socio-economical burden of diseases worldwide. The group contributes to a better understanding of cardiovascular pathophysiology at the levels of genes, proteins and signal transduction, using disease models in organs, organoids, mice and humans. The group has made significant contributions to the development of new treatment strategies for heart failure and ischemic stroke.
We study
- Cardiovascular control mechanisms, including interaction between circulation and respiration, control of cerebral blood flow, and interaction between endothelial and autonomic functions (Elstad).
- Injury of the heart in isolated perfused organs to understand and prevent ischemia and reperfusion injury, with focus on metabolism, mitochondria and the innate immune system (Stensløkken)
- Molecular mechanisms and pharmacological prevention of aortic valve calcification (Stensløkken).
- Signalosome regulation of cardiac EC-coupling, with focus on its role in contractility, arrhythmogenesis and as future drug targets (Aronsen).
- Nuclear remodelling in chronic heart disease, to determine upstream, causal nodes of disease progression (Aronsen)
- Biochemistry of blood proteases and their actions in coagulation, fibrinolysis, inflammation and vascular biology (Kanse).
- Therapeutic strategies for the treatment of ischemic stroke by promoting fibrinolysis and dampening inflammation (Kanse).
- Viability and connectivity of brain organoids in mouse models of stroke (Kanse).
Publications
Principal investigators
Published June 9, 2023 1:25 PM
- Last modified Jan. 22, 2024 12:03 PM